{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:01:47Z","timestamp":1785402107434,"version":"3.56.0"},"reference-count":57,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006784","name":"Golfers Against Cancer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006784","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/05tte0y64","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["2U54MD007605"],"award-info":[{"award-number":["2U54MD007605"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Endocrine therapy is an effective and common treatment strategy for estrogen receptor (ER)-positive breast cancers. However, the development of endocrine resistance, through genetic mutations and epigenetic alterations, in about 40% of treated patients remains a significant therapeutic challenge. Liver X receptors (LXRs) are nuclear receptors that regulate lipid metabolism and cholesterol homeostasis and have been implicated in metabolic reprogramming in breast cancers and other malignancies. We previously identified a novel LXR ligand GAC0001E5 (1E5), with potent antiproliferative activity across breast cancer subtypes. Here, we investigate its mechanisms of action in responsive (MCF-7) and endocrine-resistant (MCF-7-TamR) ER-positive breast cancer cells. Treatment with 1E5 resulted in the downregulation of LXR and its target genes, and significantly reduced ER\u03b1 expression and the expression of ER-responsive genes. Aberrant expression of androgen receptor (AR) and human epidermal growth factor receptor 2 (HER2), both implicated in endocrine resistance, were downregulated following 1E5 treatment. siRNA-mediated knockdown of LXR expression only partially recapitulated the actions of 1E5, suggesting the involvement of LXR-dependent and independent mechanisms. Collectively, these findings reveal potential crosstalk between LXR and the genetic and epigenetic regulation of pathways involved in endocrine response and alternative signaling mechanisms, highlighting potential targets in endocrine-resistant breast cancer.<\/jats:p>","DOI":"10.3390\/biom16060856","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T10:19:53Z","timestamp":1781691593000},"page":"856","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Small Molecule Liver X Receptor Modulator GAC0001E5 Targets Mechanisms of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer Cells"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6010-0503","authenticated-orcid":false,"given":"Shinjini","family":"Basu","sequence":"first","affiliation":[{"name":"Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, TX 77004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8810-9400","authenticated-orcid":false,"given":"Asitha","family":"Premaratne","sequence":"additional","affiliation":[{"name":"Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, TX 77004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9889-0467","authenticated-orcid":false,"given":"Scott","family":"Widmann","sequence":"additional","affiliation":[{"name":"Center for Biomedical and Health Research, Texas Southern University, Houston, TX 77004, USA"},{"name":"Biomolecular Research and Advanced Computing Center, Texas Southern University, Houston, TX 77004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther A.","family":"Olaleye","sequence":"additional","affiliation":[{"name":"Center for Biomedical and Health Research, Texas Southern University, Houston, TX 77004, USA"},{"name":"Biomolecular Research and Advanced Computing Center, Texas Southern University, Houston, TX 77004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4461-6216","authenticated-orcid":false,"given":"Chin-Yo","family":"Lin","sequence":"additional","affiliation":[{"name":"Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, TX 77004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e70043","DOI":"10.3322\/caac.70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41523-023-00523-4","article-title":"An emerging generation of endocrine therapies in breast cancer: A clinical perspective","volume":"9","author":"Patel","year":"2023","journal-title":"npj Breast Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of Endocrine Resistance in Breast Cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu. Rev. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41467-021-22024-3","article-title":"Epigenetic mechanisms in breast cancer therapy and resistance","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.breast.2015.07.015","article-title":"The changing role of ER in endocrine resistance","volume":"24","author":"Nardone","year":"2015","journal-title":"Breast"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1530\/ERC-18-0333","article-title":"Non-canonical AR activity facilitates endocrine resistance in breast cancer","volume":"26","author":"Chia","year":"2019","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djh166","article-title":"Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2\/neu cross-Talk in ER\/HER2\u2013positive breast cancer","volume":"96","author":"Shou","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/0008-5472.CAN-23-0184","article-title":"Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer","volume":"84","author":"Ahn","year":"2023","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3390\/receptors3030015","article-title":"Targeting liver x receptors in cancer drug discovery","volume":"3","author":"Premaratne","year":"2024","journal-title":"Receptors"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nrc3912","article-title":"Targeting liver x receptors in cancer therapeutics","volume":"15","author":"Lin","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1007\/s00432-021-03670-y","article-title":"Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer","volume":"147","author":"Shao","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_13","first-page":"1869","article-title":"Expression of LXR-\u03b2, ABCA1 and ABCG1 in human triple-negative breast cancer tissues","volume":"42","author":"Pan","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Premaratne, A., Ho, C., Basu, S., Khan, A.F., Bawa-Khalfe, T., and Lin, C.-Y. (2023). Liver x receptor inverse agonist GAC0001E5 impedes glutaminolysis and disrupts redox homeostasis in breast cancer cells. Biomolecules, 13.","DOI":"10.3390\/biom13020345"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1186\/bcr3443","article-title":"Liver \u00d7 receptor ligands disrupt breast cancer cell proliferation through an E2F-mediated mechanism","volume":"15","author":"Vedin","year":"2013","journal-title":"Breast Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/carcin\/bgp029","article-title":"The oxysterol receptor LXR inhibits proliferation of human breast cancer cells","volume":"30","author":"Vedin","year":"2009","journal-title":"Carcinogenesis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1177\/0091270009335768","article-title":"Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver x-receptor agonist, in healthy participants","volume":"49","author":"Katz","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cmet.2016.07.016","article-title":"Beneficial and adverse effects of an LXR agonist on human lipid and lipoprotein metabolism and circulating neutrophils","volume":"24","author":"Kirchgessner","year":"2016","journal-title":"Cell Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ccell.2015.05.007","article-title":"Broad anti-tumor activity of a small molecule that selectively targets the warburg effect and lipogenesis","volume":"28","author":"Flaveny","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"19530","DOI":"10.1038\/s41598-019-56038-1","article-title":"LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer","volume":"9","author":"Carpenter","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1021\/acschembio.0c00546","article-title":"Screening of focused compound library targeting liver x receptors in Pancreatic cancer identified ligands with inverse agonist and degrader activity","volume":"15","author":"Karaboga","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12964-020-00649-z","article-title":"Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer","volume":"18","author":"Bahnassy","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"D368","DOI":"10.1093\/nar\/gkad1011","article-title":"AlphaFold Protein Structure Database in 2024: Providing structure coverage for over 214 million protein sequences","volume":"52","author":"Varadi","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13321-018-0285-8","article-title":"P2Rank: Machine learning based tool for rapid and accurate prediction of ligand binding sites from protein structure","volume":"10","author":"Hoksza","year":"2018","journal-title":"J. Cheminform."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"13045","DOI":"10.1021\/acs.jcim.5c02271","article-title":"Meeko: Molecule Parametrization and Software Interoperability for Docking and Beyond","volume":"65","author":"He","year":"2025","journal-title":"J. Chem. Inf. Model."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/bioinformatics\/btp163","article-title":"Biopython: Freely available Python tools for computational molecular biology and bioinformatics","volume":"25","author":"Cock","year":"2009","journal-title":"Bioinformatics"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Eastman, P., Swails, J., Chodera, J.D., McGibbon, R.T., Zhao, Y., A Beauchamp, K., Wang, L.-P., Simmonett, A.C., Harrigan, M.P., and Stern, C.D. (2017). OpenMM 7: Rapid development of high performance algorithms for molecular dynamics. PLoS Comput. Biol., 13.","DOI":"10.1371\/journal.pcbi.1005659"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open Babel: An open chemical toolbox","volume":"3","author":"Banck","year":"2011","journal-title":"J. Cheminform."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a Cancer Dependency Map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1126\/science.aan2507","article-title":"A pathology atlas of the human cancer transcriptome","volume":"357","author":"Zhang","year":"2017","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Premaratne, A., Basu, S., Bagchi, A., Zhou, T., Feng, Q., and Lin, C.-Y. (2024). Liver x receptor ligand GAC0001E5 downregulates antioxidant capacity and ERBB2\/HER2 expression in HER2-positive breast cancer cells. Cancers, 16.","DOI":"10.3390\/cancers16091651"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0021-9258(17)38062-6","article-title":"Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor","volume":"253","author":"Horwitz","year":"1978","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1073\/pnas.86.4.1218","article-title":"Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence","volume":"86","author":"Berry","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"R66","DOI":"10.1186\/gb-2004-5-9-r66","article-title":"Discovery of estrogen receptor \u03b1 target genes and response elements in breast tumor cells","volume":"5","author":"Lin","year":"2004","journal-title":"Genome Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1158\/0008-5472.CAN-17-1327","article-title":"Tamoxifen resistance in breast cancer Is regulated by the EZH2\u2013ER\u03b1\u2013GREB1 transcriptional axis","volume":"78","author":"Wu","year":"2017","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/oncolo\/oyad049","article-title":"Revisiting androgen receptor signaling in breast cancer","volume":"28","author":"Dai","year":"2023","journal-title":"Oncologist"},{"key":"ref_38","first-page":"1","article-title":"Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells","volume":"121","author":"Thirugnansampanthan","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"216968","DOI":"10.1016\/j.canlet.2024.216968","article-title":"EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4\/6 inhibitors in ER+ breast cancer","volume":"593","author":"Belli","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_40","first-page":"1005","article-title":"The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches","volume":"20","author":"Zaczek","year":"2005","journal-title":"Histol. Histopathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/path.1370","article-title":"Expression of the HER1\u20134 family of receptor tyrosine kinases in breast cancer","volume":"200","author":"Witton","year":"2003","journal-title":"J. Pathol."},{"key":"ref_42","first-page":"1243","article-title":"Co-targeting ER and HER family receptors induces apoptosis in HER2-normal or overexpressing breast cancer models","volume":"35","author":"Chakraborty","year":"2015","journal-title":"Anticancer. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1007\/s00018-019-03429-2","article-title":"Pharmacological inhibition of androgen receptor expression induces cell death in prostate cancer cells","volume":"77","author":"Song","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1023\/A:1016119328968","article-title":"Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: An update","volume":"7","author":"Soldani","year":"2002","journal-title":"Apoptosis"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1021\/cb300541g","article-title":"A liver-selective LXR inverse agonist that suppresses hepatic steatosis","volume":"8","author":"Griffett","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.2147\/OTT.S239730","article-title":"PRMT5 promotes aerobic glycolysis and invasion of breast cancer cells by regulating the LXR\u03b1\/NF-\u03baBp65 pathway","volume":"13","author":"Han","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41591-020-01168-7","article-title":"The androgen receptor is a tumor suppressor in estrogen receptor\u2013positive breast cancer","volume":"27","author":"Hickey","year":"2021","journal-title":"Nat. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1158\/1541-7786.MCR-16-0167","article-title":"Cooperative dynamics of AR and ER activity in breast cancer","volume":"14","author":"Gordon","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"ref_49","first-page":"5887","article-title":"Inhibition of HER2\/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells","volume":"60","author":"Kurokawa","year":"2000","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"105540","DOI":"10.1016\/j.bioorg.2021.105540","article-title":"Synthesis and structure activity relationship of the first class of LXR inverse agonists","volume":"119","author":"Elgendy","year":"2022","journal-title":"Bioorganic Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"R121","DOI":"10.1186\/bcr3247","article-title":"Reversal by RAR\u03b1 agonist Am580 of c-Myc-induced imbalance in RAR\u03b1\/RAR\u03b3 expression during MMTV-Myc tumorigenesis","volume":"14","author":"Bosch","year":"2012","journal-title":"Breast Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2009.04.043","article-title":"Genomic Antagonism between Retinoic Acid and Estrogen Signaling in Breast Cancer","volume":"137","author":"Hua","year":"2009","journal-title":"Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"20637","DOI":"10.1074\/jbc.M111.227082","article-title":"Cross-talk between the androgen receptor and the liver x receptor: Implications for cholesterol homeostasis","volume":"286","author":"Krycer","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1126\/science.1241908","article-title":"27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology","volume":"342","author":"Nelson","year":"2013","journal-title":"Science"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/hep.26951","article-title":"Estrogen receptor ligands ameliorate fatty liver through a nonclassical estrogen receptor\/liver x receptor pathway in mice","volume":"59","author":"Han","year":"2014","journal-title":"Hepatology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1172\/JCI66533","article-title":"LXR\u03b2\/estrogen receptor-\u03b1 signaling in lipid rafts preserves endothelial integrity","volume":"123","author":"Ishikawa","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Menendez, J.A., Papadimitropoulou, A., Steen, T.V., Cuy\u00e0s, E., Oza-Gajera, B.P., Verdura, S., Espinoza, I., Vellon, L., Mehmi, I., and Lupu, R. (2021). Fatty acid synthase confers tamoxifen resistance to ER+\/HER2+ breast cancer. Cancers, 13.","DOI":"10.3390\/cancers13051132"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/6\/856\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:17:16Z","timestamp":1781842636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/6\/856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":57,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["biom16060856"],"URL":"https:\/\/doi.org\/10.3390\/biom16060856","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}